GlassScriptPhysician profile
Wade L Williams
NPI 1588757967
$3,101.17
in general payments reported to CMS, 2019-2025
30 companies · $96.81 in 2025
The $96.81 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,662 · 2020: $637 · 2021: $479 · 2022: $49.69 · 2023: $135 · 2024: $41.85 · 2025: $96.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $251 · Education: $22.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $251.23 |
| Education | $22.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $702.19 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $358.05 | 2019-2025 | Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.74 | 2019-2023 | Ofev |
| Sunovion Pharmaceuticals INC. | $256.71 | 2019-2020 | |
| Genentech USA, INC. | $218.38 | 2019-2023 | Xolair |
| Grifols USA, LLC | $197.89 | 2019-2021 | |
| Insmed, INC. | $163.83 | 2019-2022 | |
| Philips North America LLC | $127.49 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $121.17 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $106.72 | 2019 | |
| Pulmonx Corporation | $49.30 | 2019-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Intuitive Surgical, INC. | $41.12 | 2025 | |
| Emd Serono, INC. | $38.50 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $37.62 | 2021 | |
| Advanced Respiratory, INC | $36.32 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $33.84 | 2019 | |
| Covis Pharma Gmbh | $31.36 | 2022 | |
| Sanofi Pasteur INC. | $30.56 | 2019-2020 | |
| Resmed Corp | $22.68 | 2024 | |
| Jazz Pharmaceuticals INC. | $21.85 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $20.77 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.53 | 2019 | |
| Amgen INC. | $16.75 | 2025 | Tezspire |
| Janssen Pharmaceuticals, INC | $16.03 | 2020 | |
| Abbvie INC. | $14.27 | 2021 | |
| La Jolla Pharmaceutical Company | $13.60 | 2019 | |
| Electromed, INC. | $12.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.38 | 2020 | |
| Sk Life Science, INC. | $11.99 | 2021 | |
| Mylan Specialty L.P. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wade Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.